Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013

被引:35
|
作者
Forrester, T. [1 ,4 ]
Siskind, D. [2 ,3 ]
Winckel, K. [1 ,4 ]
Wheeler, A. [5 ,6 ]
Hollingworth, S. [4 ]
机构
[1] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
[2] Metro South Addict & Mental Hlth Serv, Brisbane, Qld, Australia
[3] Univ Queensland, Sch Med, Brisbane, Qld, Australia
[4] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
[5] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia
[6] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand
关键词
clozapine; antipsychotic; pharmacoepidemiology; schizophrenia; NATIONAL-SURVEY; SCHIZOPHRENIA; ADHERENCE; THERAPY; COSTS;
D O I
10.1055/s-0035-1554713
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Clozapine is the most effective treatment for treatment-resistant schizophrenia but its use is suboptimal. Methods: Clozapine dispensing data from Queensland, Australia were extracted (2004-2013). The number of people dispensed clozapine each year and mean maintenance doses were calculated. The 18-week and 5-year cessation and treatment interruption rates were calculated using Kaplan-Meier analysis. Results: Clozapine dispensings increased 36.4 % (p < 0.001) from 44 to 60 people per 100 000. This was estimated as 8.3 % of people with schizophrenia and 33.3 % of people with treatment resistant schizophrenia dispensed clozapine in 2013. Mean maintenance dose did not significantly change (364-399 mg) over 5 years of treatment. One in 7 (14.2 %) people ceased within the first 3 weeks. 3-quarters (72.7 %) reached maintenance therapy. The 5-year actuarial estimate of the proportion of people a) dispensed clozapine was 0.610 (S.E. 0.011) and b) with an interruption to treatment was 0.422 (S.E. 0.013). Discussion: The number of patients being dispensed clozapine increased between 2004 and 2013 but clozapine is still underused. Increased use combined with continued monitoring for adverse effects will improve quality use of clozapine.
引用
收藏
页码:164 / 169
页数:6
相关论文
共 50 条
  • [31] EVOLUTION OF BPH HEALTHCARE COSTS: 2004-2013
    Bajic, P.
    Wegrzyn, G.
    Nelson, M.
    Dornbier, R.
    Mahon, J.
    Feinstein, L.
    Ward, J.
    Fwu, C.
    Kirkali, Z.
    Bavendam, T.
    Matlaga, B.
    Welliver, C.
    Farooq, A.
    McVary, K.
    [J]. JOURNAL OF SEXUAL MEDICINE, 2020, 17 (01): : S37 - S37
  • [32] DC Towers Vienna, Austria 2004-2013
    不详
    [J]. A + U-ARCHITECTURE AND URBANISM, 2009, (468): : 98 - 101
  • [33] Intracranial Subependymoma: A SEER Analysis 2004-2013
    Ha Son Nguyen
    Doan, Ninh
    Gelsomino, Michael
    Shabani, Saman
    [J]. WORLD NEUROSURGERY, 2017, 101 : 599 - 605
  • [34] PHARMACOVIGILANCE OF LAMOTRIGINE AND VALPROATE IN NORWAY, 2004-2013
    Lima, M.
    Baftiu, A.
    Svendsen, K.
    Johannessen S, I.
    Landmark, Johannessen C.
    [J]. EPILEPSIA, 2016, 57 : 184 - 184
  • [35] 河洛大鼓研究综述(2004-2013)
    包婷
    [J]. 交响(西安音乐学院学报), 2014, 33 (02) : 100 - 107
  • [36] Measuring energy poverty in Japan, 2004-2013
    Okushima, Shinichiro
    [J]. ENERGY POLICY, 2016, 98 : 557 - 564
  • [37] Trends in dispensing and utilization of tapentadol in Australia
    Camacho, Ximena
    Schaffer, Andrea
    Buckley, Nicholas A.
    Pratt, Nicole
    Henry, David
    Pearson, Sallie-Anne
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 543 - 544
  • [38] Trends in incidence of ischaemic stroke among people with Type 2 diabetes in Scotland, 2004-2013
    Read, S. H.
    Kerssens, J. J.
    McAllister, D. A.
    Walker, J. J.
    Wild, S. H.
    [J]. DIABETIC MEDICINE, 2017, 34 : 24 - 24
  • [39] Satellite-Based Spatiotemporal Trends in PM2.5 Concentrations: China, 2004-2013
    Ma, Zongwei
    Hu, Xuefei
    Sayer, Andrew M.
    Levy, Robert
    Zhang, Qiang
    Xue, Yingang
    Tong, Shilu
    Bi, Jun
    Huang, Lei
    Liu, Yang
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 2016, 124 (02) : 184 - 192
  • [40] TRENDS IN THE EPIDEMIOLOGY OF TYPE 1 DIABETES MELLITUS IN MOSCOW REGION DURING THE PERIOD 2004-2013
    Misnikova, I.
    Dreval, A.
    Kovaleva, Y. U.
    Gubkina, V.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A126 - A127